Novartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitis

  • New Cosentyx® (secukinumab) US label to include 300 mg up-titration option is based on Phase III MEASURE 3 study results in ankylosing spondylitis (AS)1
     
  • Label update provides clinicians with greater choice for their patients, based on clinical response to treatment
     
  • Novartis has submitted to FDA and EMA for approval in non-radiographic axial spondyloarthritis (nr-axSpA)2,3; potentially providing patients with a treatment that addresses the axSpA disease spectrum
     

    • …

/by

Sandoz completes acquisition of Aspen’s Japanese operations, strengthening its position in world’s third largest market for generics and off-patent medicines

  • Successful acquisition of Aspen’s Japanese operations and assets reinforces strategic focus on Japan, world’s third largest market for generics and off-patent medicines
  • Acquired portfolio complements existing Sandoz portfolio and consists primarily of off-patent branded medicines with focus on anaesthetics and specialty brands
  • Transaction enables Sandoz to increase portfolio and pipeline offerings in hospital setting, expanding number of patients who can gain access to these important medicines  

Holzkirchen, …

/by

Sandoz officially recognized as Global Top Employer 2020

  • Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally
  • People-first policies such as global equal parental leave for 14 weeks and joining the Equal Pay International Coalition contributed to recognition
  • Second such annual certification for Sandoz, underlining ongoing commitment to attract and keep best talent by building a great place to work

Holzkirchen, January 30, 2020 – Sandoz, a Novartis division, is pleased to announce that it has been officially awarded the “Global Top Employer 2020” …

/by

Sandoz officially recognized as Global Top Employer 2020

  • Sandoz officially recognized by Top Employers Institute for its exceptional employee offerings globally
  • People-first policies such as global equal parental leave for 14 weeks and joining the Equal Pay International Coalition contributed to recognition
  • Second such annual certification for Sandoz, underlining ongoing commitment to attract and keep best talent by building a great place to work

Holzkirchen, January 30, 2020 – Sandoz, a Novartis division, is pleased to announce that it has been officially awarded the “Global Top Employer 2020” …

/by

Novartis 2019 Financial Results

Download the media release
English (PDF 0.1 MB )  |  Deutsch (PDF 0.1 MB)  |  Français (PDF 0.1 MB)

Condensed financial report (PDF 0.7 MB) …

/by

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

  • Full year net sales for continuing operations1 up 9% (cc2, +6% USD):
    • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
    • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
    • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …
/by

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

  • Full year net sales for continuing operations1 up 9% (cc2, +6% USD):
    • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
    • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
    • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …
/by

Novartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019

  • Full year net sales for continuing operations1 up 9% (cc2, +6% USD):
    • Pharmaceuticals BU growing 12% (cc) driven by Cosentyx USD 3.6 billion (+28% cc), Entresto USD 1.7 billion (+71% cc) and Zolgensma USD 361 million
    • Oncology BU growing 10% (cc) driven by Promacta/Revolade USD 1.4 billion (+23% cc), Kisqali USD 0.5 billion (+111% cc) and Lutathera USD 0.4 billion (+160% cc)
    • Sandoz sales grew 2% (cc, -1% USD) driven by Biopharmaceuticals …
/by

Novartis at the World Economic Forum Annual Meeting Davos 2020

Planting a Better Future

Novartis CEO Vas Narasimhan moderated a panel of some of the youngest leaders to discuss which actions should leaders prioritize to secure prosperity for the next generation.

Watch the session

/by

Novartis announces EU approval of Mayzent® (siponimod) for adult patients with secondary progressive multiple sclerosis (SPMS) with active disease

  • Mayzent® (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple sclerosis (SPMS) with active disease in Europe1
     
  • Mayzent addresses an unmet need for SPMS patients with active disease who, until now, did not have an oral treatment that has been shown to be effective in delaying progression in this patient population
     
  • Approval is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad range of SPMS patients, …
/by